重症COVID-19 ICU患者侵袭性肺部真菌感染的发生情况
法国5个ICU纳入145例SARS-CoV-2相关肺炎有创机械通气患者,其中54%接受ECMO,仅14%存在侵袭性真菌感染宿主危险因素。共完成2815项真菌学检测(培养、半乳甘露聚糖、β-葡聚糖、PCR),7例(4.8%)诊断可能/推测侵袭性肺霉菌感染且病死率高。多因素分析显示实体器官移植受者风险显著增高(OR 4.66,P=0.004)。25例(17.2%)出现假阳性真菌检测或临床无关定植,未启动抗真菌治疗。结论:无免疫抑制的重症COVID-19患者侵袭性真菌继发感染风险低,尤其曲霉病。
要点
- 145例重症COVID-19有创机械通气患者中仅7例(4.8%)诊断可能/推测侵袭性肺霉菌感染,且与高病死率相关。
- 实体器官移植受者侵袭性真菌感染风险显著增高(OR 4.66,P=0.004),应作为重点筛查人群。
- 25例(17.2%)出现假阳性真菌检测或临床无关定植,未启动抗真菌治疗,提示需谨慎解读阳性结果。
- 仅14%(20/145)患者存在预存侵袭性真菌感染宿主危险因素,无免疫抑制者总体风险低。
- 所有患者均接受有创机械通气,54%(73例)接受ECMO支持,病情严重但真菌感染率仍低。
适用人群与场景
- 法国5个ICU收治的SARS-CoV-2相关肺炎成人患者,均接受有创机械通气,中位年龄55岁,72%男性,68%超重,57%高血压,32%糖尿病;54%接受ECMO支持。
- 仅14%(20例)存在预存侵袭性真菌感染宿主危险因素;原文未明确列出排除标准。
诊断标准与关键阈值
- 原文未提及具体诊断标准名称或评分界值;仅描述通过培养、半乳甘露聚糖、β-葡聚糖和PCR检测呼吸样本和血清进行真菌学筛查。
处置流程与药物剂量
- 原文未提及具体抗真菌药物、剂量、给药途径或疗程;仅提到假阳性或临床无关定植患者未启动抗真菌治疗。
红旗征与不能漏的情况
- 可能/推测侵袭性肺霉菌感染与高病死率相关(原文未给出具体病死率数值)。
- 假阳性真菌检测或临床无关定植常见(17.2%),避免不必要的抗真菌治疗。
研究设计与关键结果
- 研究类型:多中心观察性研究(原文未明确设计类型),法国5个ICU,样本量145例。
- 干预:对呼吸样本和血清进行真菌学筛查(培养、半乳甘露聚糖、β-葡聚糖、PCR),共2815项检测(475份呼吸样本,532份血清)。
- 其他:25例(17.2%)假阳性或临床无关定植,未启动抗真菌治疗。
证据类型、等级与局限
- 证据类型:多中心观察性研究(原文未明确RCT/队列等标签),样本量145例,来自5个ICU。
- 局限:原文未提及具体证据等级;观察性设计无法确立因果关系;单国多中心;真菌感染事件数少(7例);未设对照干预组。
对床旁实践的改变
- 对无基础免疫抑制的重症COVID-19患者,不必常规经验性抗真菌治疗,因侵袭性真菌感染率低(4.8%)。
- 对实体器官移植受者应加强真菌学筛查,因其风险显著增高(OR 4.66)。
- 对真菌检测阳性结果需结合临床判断,警惕假阳性或定植(17.2%),避免不必要的抗真菌暴露。
指南或共识出处
- 原文未提及指南或共识名称;研究发表于Am J Respir Crit Care Med。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Whether severe coronavirus disease (COVID-19) is a significant risk factor for the development of invasive fungal superinfections is of great medical interest and remains, for now, an open question.Objectives: We aim to assess the occurrence of invasive fungal respiratory superinfections in patients with severe COVID-19.Methods: We conducted the study on patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia admitted to five ICUs in France who had respiratory and serum sampling performed for specific screening of fungal complications.Measurements and Main Results: The study population included a total of 145 patients; the median age was 55 years old. Most of them were male (n = 104; 72%), were overweight (n = 99; 68%), and had hypertension (n = 83; 57%) and diabetes (n = 46; 32%). Few patients presented preexisting host risk factors for invasive fungal infection (n = 20; 14%). Their global severity was high; all patients were on invasive mechanical ventilation, and half (n = 73, 54%) were on extracorporeal membrane oxygenation support. Mycological analysis included 2,815 mycological tests (culture, galactomannan, β-glucan, and PCR) performed on 475 respiratory samples and 532 sera. A probable/putative invasive pulmonary mold infection was diagnosed in 7 (4.8%) patients and linked to high mortality. Multivariate analysis indicates a significantly higher risk for solid organ transplant recipients (odds ratio, = 4.66; interquartile range, 1.98-7.34; P = 0.004). False-positive fungal test and clinically irrelevant colonization, which did not require the initiation of antifungal treatment, was observed in 25 patients (17.2%).Conclusions: In patients with no underlying immunosuppression, severe SARS-CoV-2-related pneumonia seems at low risk of invasive fungal secondary infection, especially aspergillosis.
参考来源
- Fekkar A, Lampros A, Mayaux J, et al. Occurrence of Invasive Pulmonary Fungal Infections in Patients with Severe COVID-19 Admitted to the ICU. Am J Respir Crit Care Med. 2021. PMID: 33480831. doi:10.1164/rccm.202009-3400OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。